InterCure Ltd. (INCR)
USD 1.42
(-1.05%)
USD 1.42
(-1.05%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 195.67 Million ILS | -23.31% |
| 2022 | 255.16 Million ILS | 134.28% |
| 2021 | 108.91 Million ILS | 1530.66% |
| 2020 | 6.67 Million ILS | -60.83% |
| 2019 | 17.05 Million ILS | 33.45% |
| 2018 | 12.77 Million ILS | 335.05% |
| 2017 | 2.93 Million ILS | 22.75% |
| 2016 | 2.39 Million ILS | 0.0% |
| 2015 | - ILS | -100.0% |
| 2014 | 350.45 Thousand ILS | 0.0% |
| 2013 | - ILS | -100.0% |
| 2012 | 1.31 Million ILS | -96.74% |
| 2011 | 40.3 Million ILS | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 133.07 Million ILS | 13.33% |
| 2024 Q1 | 133.07 Million ILS | -21.9% |
| 2023 Q3 | 191.03 Million ILS | 17.32% |
| 2023 Q2 | 162.84 Million ILS | -16.55% |
| 2023 FY | 195.67 Million ILS | -23.31% |
| 2023 Q1 | 195.12 Million USD | -23.53% |
| 2023 Q4 | 170.39 Million ILS | -10.8% |
| 2022 Q3 | 201.23 Million ILS | 24.65% |
| 2022 Q4 | 255.16 Million ILS | 26.8% |
| 2022 Q1 | 126.66 Million ILS | 16.3% |
| 2022 Q2 | 161.44 Million ILS | 27.45% |
| 2022 FY | 255.16 Million ILS | 134.28% |
| 2021 Q3 | 79.47 Million ILS | 51.9% |
| 2021 Q4 | 108.91 Million ILS | 37.04% |
| 2021 Q1 | 11.29 Million ILS | 69.13% |
| 2021 FY | 108.91 Million ILS | 1530.66% |
| 2021 Q2 | 52.31 Million ILS | 363.16% |
| 2020 FY | 6.67 Million ILS | -60.83% |
| 2020 Q2 | 16.83 Million ILS | -1.42% |
| 2020 Q3 | 18.64 Million ILS | 10.73% |
| 2020 Q4 | 6.67 Million ILS | -64.18% |
| 2020 Q1 | 17.08 Million ILS | 0.18% |
| 2019 FY | 17.05 Million ILS | 33.45% |
| 2019 Q3 | 3.57 Million ILS | -74.19% |
| 2019 Q4 | 17.05 Million ILS | 377.55% |
| 2019 Q1 | 3.57 Million ILS | -72.06% |
| 2019 Q2 | 13.83 Million ILS | 287.48% |
| 2018 Q2 | 3.36 Million ILS | -22.38% |
| 2018 Q3 | 12.77 Million ILS | 279.64% |
| 2018 Q4 | 12.77 Million ILS | 0.0% |
| 2018 FY | 12.77 Million ILS | 335.05% |
| 2018 Q1 | 4.33 Million ILS | 47.64% |
| 2017 Q1 | 3.3 Million ILS | 38.21% |
| 2017 Q3 | 3.08 Million ILS | -3.15% |
| 2017 Q4 | 2.93 Million ILS | -4.77% |
| 2017 FY | 2.93 Million ILS | 22.75% |
| 2017 Q2 | 3.18 Million ILS | -3.7% |
| 2016 Q3 | 2.7 Million ILS | 2.05% |
| 2016 FY | 2.39 Million ILS | 0.0% |
| 2016 Q4 | 2.39 Million ILS | -11.49% |
| 2016 Q2 | 2.64 Million ILS | 6.65% |
| 2016 Q1 | 2.48 Million ILS | 0.0% |
| 2015 Q4 | - ILS | 0.0% |
| 2015 Q3 | - ILS | 0.0% |
| 2015 Q1 | 241.36 Thousand ILS | -31.13% |
| 2015 FY | - ILS | -100.0% |
| 2015 Q2 | - ILS | -100.0% |
| 2014 Q4 | 350.45 Thousand ILS | 90.18% |
| 2014 Q3 | 184.27 Thousand ILS | 7.36% |
| 2014 Q2 | 171.63 Thousand ILS | 0.0% |
| 2014 Q1 | - ILS | 0.0% |
| 2014 FY | 350.45 Thousand ILS | 0.0% |
| 2013 Q4 | - ILS | 0.0% |
| 2013 FY | - ILS | -100.0% |
| 2013 Q1 | 1.34 Million ILS | 2.52% |
| 2013 Q2 | - ILS | -100.0% |
| 2013 Q3 | - ILS | 0.0% |
| 2012 FY | 1.31 Million ILS | -96.74% |
| 2012 Q2 | 328.76 Thousand ILS | 0.0% |
| 2012 Q3 | 328.76 Thousand ILS | 0.0% |
| 2012 Q4 | 1.31 Million ILS | 300.0% |
| 2012 Q1 | 328.76 Thousand ILS | -96.74% |
| 2011 Q1 | 10.07 Million ILS | 0.0% |
| 2011 FY | 40.3 Million ILS | 0.0% |
| 2011 Q2 | 10.07 Million ILS | 0.0% |
| 2011 Q3 | 10.07 Million ILS | 0.0% |
| 2011 Q4 | 10.07 Million ILS | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Theratechnologies Inc. | 58.96 Million USD | -231.836% |
| Harrow Health, Inc. | 190.5 Million USD | -2.717% |
| Dynavax Technologies Corporation | 256.91 Million USD | 23.836% |
| Biofrontera Inc. | 5.39 Million USD | -3524.319% |
| Cronos Group Inc. | 2.53 Million USD | -7604.007% |
| Sonoma Pharmaceuticals, Inc. | 608 Thousand USD | -32083.717% |
| Ironwood Pharmaceuticals, Inc. | 715.53 Million USD | 72.653% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -438.714% |
| RedHill Biopharma Ltd. | 1.17 Million USD | -16581.671% |
| Cumberland Pharmaceuticals Inc. | 18.42 Million USD | -961.818% |
| Radius Health, Inc. | 365.31 Million USD | 46.436% |
| Universe Pharmaceuticals INC | 5.48 Million USD | -3469.149% |
| DURECT Corporation | 20.74 Million USD | -843.204% |
| ProPhase Labs, Inc. | 21.38 Million USD | -815.234% |
| Safety Shot Inc | 1.54 Million USD | -12532.685% |
| Phibro Animal Health Corporation | 525.45 Million USD | 62.761% |
| China SXT Pharmaceuticals, Inc. | 2.64 Million USD | -7291.136% |
| Alvotech | 1.07 Billion USD | 81.806% |
| Assertio Holdings, Inc. | 40.91 Million USD | -378.288% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -371.204% |
| Rockwell Medical, Inc. | 13.43 Million USD | -1356.038% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -29651.484% |
| Procaps Group S.A. | 285.93 Million USD | 31.566% |
| Intra-Cellular Therapies, Inc. | 16.93 Million USD | -1055.254% |
| SCYNEXIS, Inc. | 15.08 Million USD | -1197.593% |
| Aytu BioPharma, Inc. | 15.12 Million USD | -1193.39% |
| Viatris Inc. | 18.12 Billion USD | 98.92% |
| OptiNose, Inc. | 131.74 Million USD | -48.523% |
| SIGA Technologies, Inc. | 1.46 Million USD | -13265.833% |
| Tilray Brands, Inc. | 387.31 Million USD | 49.479% |
| PetIQ, Inc. | 468.3 Million USD | 58.216% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -29651.484% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 54.324% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Alimera Sciences, Inc. | 67.39 Million USD | -190.326% |
| Collegium Pharmaceutical, Inc. | 674.28 Million USD | 70.98% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.08 Million USD | -17890.078% |
| Organogenesis Holdings Inc. | 119.35 Million USD | -63.951% |
| Journey Medical Corporation | 17.73 Million USD | -1003.649% |
| Petros Pharmaceuticals, Inc. | 8.27 Million USD | -2264.222% |
| Alpha Teknova, Inc. | 30.45 Million USD | -542.449% |
| Clever Leaves Holdings Inc. | 2.08 Million USD | -9275.994% |
| Lifecore Biomedical, Inc. | 130.36 Million USD | -50.105% |
| PainReform Ltd. | 86 Thousand USD | -227431.395% |
| Cosmos Health Inc. | 12.42 Million USD | -1474.998% |
| Avadel Pharmaceuticals plc | 35.38 Million USD | -453.01% |
| TherapeuticsMD, Inc. | 8 Million USD | -2344.435% |
| Embecta Corp. | 1.63 Billion USD | 88.058% |
| Regencell Bioscience Holdings Limited | 59.8 Thousand USD | -327080.765% |
| Talphera, Inc. | - USD | -Infinity% |
| Pacira BioSciences, Inc. | 586.04 Million USD | 66.611% |
| Incannex Healthcare Limited | 373 Thousand USD | -52360.322% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -18840.486% |
| Shineco, Inc. | 29.65 Million USD | -559.813% |
| Procaps Group, S.A. | 285.93 Million USD | 31.566% |
| ANI Pharmaceuticals, Inc. | 315.32 Million USD | 37.945% |
| Aquestive Therapeutics, Inc. | 98.82 Million USD | -98.01% |
| Lantheus Holdings, Inc. | 616.94 Million USD | 68.283% |
| Alvotech | 1.07 Billion USD | 81.806% |
| Hempacco Co., Inc. | 13.72 Million USD | -1325.749% |
| Eagle Pharmaceuticals, Inc. | 62.46 Million USD | -213.254% |
| Bright Green Corporation | 1.85 Million USD | -10466.951% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 63.827% |
| Kamada Ltd. | 8.74 Million USD | -2136.568% |
| Indivior PLC | 281.6 Million USD | 30.513% |
| Evoke Pharma, Inc. | 5 Million USD | -3813.54% |
| Flora Growth Corp. | 3.67 Million USD | -5228.894% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -18840.486% |
| Evolus, Inc. | 126.54 Million USD | -54.629% |
| HUTCHMED (China) Limited | 86.13 Million USD | -127.185% |
| Amphastar Pharmaceuticals, Inc. | 623.64 Million USD | 68.624% |
| Akanda Corp. | 3.99 Million USD | -4793.404% |